Introduction
Klebsiella pneumoniae carbapenemases (KPCs) are class A b-lactamases that confer resistance to penicillins, extendedspectrum cephalosporins, carbapenems and monobactams. They were first detected in 1996 in the USA and since then they have been increasingly reported worldwide, and are becoming endemic in hospitals in the North-East of the USA, Israel and Greece. 1 In Europe, KPCs have been described since 2005 in France, Finland, Germany, Greece, Italy, Norway, Poland, Sweden and the UK. 2 -9 Their recent emergence in some of these countries seems to be linked to persons who have travelled to endemic areas. 2, 3, 5, 8, 9 The rapid spread of these enzymes is of concern since infections caused by KPC producers are difficult to treat due to the scarce therapeutic options available and the high rate of associated morbidity. 1 Various KPC variants differing in one or two amino acids (KPC-2, -3, -4, -5, -6, -7, -8, -9 and -10) have been mainly identified in K. pneumoniae and to a lesser extent in Pseudomonas aeruginosa and Acinetobacter baumannii clinical isolates, in which KPC-2 and KPC-3 are the most widespread variants. 1, 10 While KPC-2 is more frequently detected in the USA, KPC-3 has # The Author 2010. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org J Antimicrob Chemother 2010; 65: 1608 -1614 doi:10.1093/jac/dkq174 Advance Access publication 30 May 2010 been more commonly identified in Israel although recent studies have detected KPC-3 producers in South and North America and several European countries. 3, 5, 7 Both bla KPC genes have been found as part of Tn4401, a Tn3-like element of 10 kb, which has been detected among different conjugative and nonconjugative plasmids. 10 -14 However, the enzyme encoded by bla KPC-3 appears to confer a lower level of carbapenem resistance than that encoded by bla KPC-2 .
11,12 Clonal expansion of the K. pneumoniae ST258 clone and the spread of particular plasmids seem to have mainly fuelled the rapid dissemination of these genes worldwide. 1, 14 Here, we describe the emergence of bla KPC-3 in Spain associated with a Tn4401 variant usually linked to bla KPC-2 , but located in a similar plasmid context to that previously described for bla . Such emergence was associated with an outbreak of two K. pneumoniae clones not previously associated with bla KPC genes. One is an apparently new highly transmissible clone and the other is a persistently recovered clone in our institution associated with a CTX-M extended-spectrum b-lactamase (ESBL). It can be hypothesized that the spread of these bla KPC-3 -Tn4401a widespread plasmids into different clones might increase the risk of broader dissemination of KPC-mediated carbapenem resistance.
Materials and methods

Bacterial strains, epidemiological background, clinical data and control measures
Twelve clinical isolates resistant to imipenem, meropenem and ertapenem (MIC ≥8 mg/L) and negative for the expression of metallo-b-lactamase (MBL) enzymes were recovered from clinical and colonization surveillance cultures from September 2009 to February 2010 from eight hospitalized patients in the tertiary Ramó n y Cajal University Hospital, Madrid (Spain). Isolates were recovered from urine (n ¼3), faeces (n¼3), pharynx (n¼3), wound (n¼2) and blood (n ¼1) (see Table 2 ). Bacterial identification was performed using the semiautomated WIDER system (Fco. Soria-Melguizo, Madrid, Spain). Relatedness among isolates was established by XbaI and SpeI PFGE as previously described 15 and PFGE patterns were interpreted according to the criteria proposed by Tenover et al. 16 with closely and possibly related patterns being considered as belonging to a single clone. Isolates were also characterized by multilocus sequence typing (MLST) according to the protocol described for K. pneumoniae (http://www.pasteur.fr/recherche/ genopole/PF8/mlst/Kpneumoniae.html).
Clinical records of patients with infection and/or colonization with these isolates were reviewed and the following data were included: age, sex, underlying disease, patient location (hospital ward), length of stay (LOS), LOS until the first positive culture, infection and colonization sites, use of antibiotics in the 2 weeks before culturing carbapenemresistant K. pneumoniae isolates, and the antibiotic therapy directed to control the clinically significant isolate.
Infection control measures, including contact isolation, barrier precaution and rectal and pharyngeal surveillance cultures in infected patients and those admitted to the same unit 17, 18 were immediately implemented after the detection of the first case. Samples from surveillance cultures were directly inoculated onto MacConkey agar plates supplemented with ceftazidime (4 mg/L) and using previous broth enrichment in brain heart infusion (BHI) supplemented with imipenem (1 mg/L). Colonies recovered on ceftazidime-containing MacConkey plates were screened for carbapenemase production.
Antibiotic susceptibility and screening for carbapenemase production Antibiotic susceptibility testing was performed by standard microdilution and Etest. Clinical categorization was performed using the EUCAST clinical breakpoints (www.eucast.org). The epidemiological cut-off value (ECOFF) was also used in the absence of a EUCAST breakpoint. Phenotypic carbapenemase production was assessed by the modified Hodge test as recommended by the CLSI and disc diffusion-based methods using boronic acid and EDTA. 19 -21 In addition, the presence of ESBLs was also screened. 19 Antibiotics were provided by the manufacturers or purchased from Sigma-Aldrich, Inc. (St Louis, MO, USA).
Characterization of antibiotic resistance genes and bla KPC genetic environment
The presence of genes encoding class A (TEM, SHV, CTX-M and KPC), B (IMP and VIM) and D (OXA-9) b-lactamases was determined by PCR using specific primers. 22, 23 The presence of qnr genes was investigated by multiplex PCR as previously described. 24 The genetic environment of bla KPC was sought by long-PCR mapping based on the sequence of Tn4401 (Table 1 and see Figure 2 ). All PCR products were sequenced and compared with available sequences in the GenBank database.
Transferability of the bla KPC gene and plasmid characterization
Transfer of bla KPC was assayed by a filter-mating protocol at a 1:10 donor/ recipient ratio for 24 h at 378C. Clinical isolates were used as plasmid donors and an Escherichia coli K-12 strain BM21 (rifampicin and nalidixic acid resistant and plasmid free) was used as recipient. Transconjugants were selected on Luria-Bertani (LB) plates supplemented with ceftazidime (2 mg/L), imipenem (2 mg/L) or meropenem (1 mg/L) and rifampicin (100 mg/L; Sigma, Poole, UK) after incubation at 378C for 24 h. Location of bla KPC was determined by hybridization of S1-digested DNA or plasmid DNA from clinical isolates with specific probes for the b-lactamases genes. respectively. Correspondence of PCR products with plasmids harboured by the cell was determined by hybridization of S1-digested DNA or plasmid DNA with specific probes. Comparison of XhoI-and HindIIIdigested plasmid DNA was performed to assess similarity between plasmids.
Molecular techniques
Genomic DNA was extracted using a QIAamp DNA mini kit (QIAGEN, Hilden, Germany). Plasmid DNA was obtained by using a modified protocol of the alkaline lysis method from an overnight LB culture supplemented with ceftazidime (2 mg/L) plus meropenem (1 mg/L). 14 PCR assays to amplify fragments ,2 kb were carried out using the conditions previously described. 27 Long-PCR assays (.2 kb) were performed using 2.5 mM MgCl 2 , 0.2 mM of each deoxynucleoside triphosphate, 0.1 mM each primer, 2.5 U of Takara LA Taq polymerase (Takara Bio Inc., Shiga, Japan) and the following conditions: 1 min at 948C; 30 cycles of 20 s at 968C, 1 min at 52-608C and 1.5-4 min at 728C; and a final step of 10 min at 728C. Primers used are listed in Table 1 . The probes used in the hybridization assays were generated by PCR using positive controls as template DNA. 5 Southern blot DNA transfer and hybridization were performed by standard procedures. 28 Labelling and detection were carried out using Gene Images Alkphos Direct Labelling system kit, following the manufacturer's instructions (Amersham Life Sciences, Uppsala, Sweden).
Sequence analysis
GenBank searches were performed with the NCBI BLASTN alignment tool. The sequence of Tn4401a containing bla KPC-3 shown in Figure 2 is available at the GenBank database as GU386376.
Results and discussion
Bacterial strains, epidemiological background and clinical data All isolates were resistant to all b-lactams tested by standard microdilution including imipenem, meropenem and aztreonam (MICs≥ 8 mg/L), but displayed lower carbapenem MICs when susceptibility was determined using Etest (MIC range 0.5-2 mg/L). Nevertheless, colonies growing within the zone of inhibition were found in all isolates, denoting the hetero-resistance in the expression of carbapenem resistance that complicates the detection of carbapenemase-producing isolates. 1, 29, 30 The modified Hodge test and the boronic acid disc diffusion assay were positive. In contrast, the disc diffusion assays to detect the phenotypic pattern of either MBL (using EDTA and either imipenem or ceftazidime) or ESBL were negative. Unlike the situation previously described for carbapenemase-producing isolates, 3, 5, 7, 11, 12, 31 11 of these isolates were susceptible to amikacin and tobramycin and to both nalidixic acid and ciprofloxacin, as well as to trimethoprim/sulfamethoxazole. Moreover, they were resistant to tetracycline and minocycline and showed an intermediate level of susceptibility to tigecycline (MIC ¼ 2 mg/L). All these isolates were considered clonally related and they were assigned to the new sequence type ST384 (Figure 1) , which might represent an emerging highly transmissible K. pneumoniae clone. The other isolate had the same susceptibility profile, but was resistant to quinolones. It showed a different PFGE pattern and was also identified as a different ST (ST388). It is remarkable that this ST388 strain corresponded to a persistent CTX-M-10-producing K. pneumoniae clone found in our institution since 1998 (A. Valverde, T. M. Coque and R. Canton, unpublished data). Allelic profiles of both ST384 and ST388 are shown in Table 2 .
The emergence of KPC-producing isolates in our institution is not associated with the pandemic spread of K. pneumoniae ST258 clone, which has predominantly been identified among KPC-2 and KPC-3 producers from the USA, other European countries (Finland, Hungary, Italy, Norway, Poland and Sweden) and Israel, and among CTX-M-15 producers in Hungary. 5 -7,14,32,33 ST258 is a single locus variant of the also widespread ST11, which has been extensively associated with CTX-M-15 in various countries including Spain. 34 In contrast to our isolates and those recently described in California, ST258 KPC-producing strains are commonly resistant to both aminoglycosides and quinolones, although this resistance profile seems to be linked in some cases to the clonal background instead of to the plasmid carrying bla KPC . 7,35 -37 Indeed, the presence of bla KPC genes in different clones increases the risk of a broader dissemination of this carbapenemase-mediated resistance. 32 In our study, patients with positive cultures of these K. pneumoniae isolates were hospitalized in five different wards (Oncology, Internal Medicine, Paediatrics, Vascular Surgery Curiao et al. Table 2 summarizes the clinical features of these patients. Unlike in previous reports 2,3,8 none of these patients had a history of a recent journey to countries where KPC producers are widely spread, indicating circulation of KPC-producing isolates within the clinical environment in our country. All but one patient were elderly (.65 years) and all had multiple underlying illnesses and a prolonged hospital stay (range 10-68 days), including one patient (designated as patient no. 7 in Table 2 ) admitted to the emergency room who had recent periods of hospitalization. In six patients, the first positive culture for carbapenemase-producing K. pneumoniae was obtained close to the time of hospital discharge (range 10 -61 days) ( Table 2 ). Six out of the eight patients were previously treated with broad-range antibiotics including carbapenems. Urinary tract infection was documented in two patients who were successfully treated with ciprofloxacin, whereas in one case the carbapenemase-producing K. pneumoniae isolate was associated with a therapy-refractory bacteraemic episode (Table 2) . In all cases, infection control practices were implemented after the recovery of these isolates. 17 Three patients were found to be colonized with carbapenemaseproducing K. pneumoniae in surveillance cultures. Overall, rectal and pharyngeal colonization was detected in two patients each, another single patient being colonized in both locations. Despite the implementation of epidemiological measures currently recommended for control of infections with carbapenemresistant Enterobacteriaceae we apparently failed to control the outbreak of these isolates. 17, 18 b-Lactamase genes and other resistance genes Carbapenemase activity was due to the presence of KPC-3 in all of the isolates studied, which also contained the bla OKP-5 , bla OXA-9 and bla TEM-1 genes. The bla KPC , bla OXA and bla TEM genes were located on the same plasmid as described in other studies and both showed identical sequences to those located in the recently sequenced plasmid pKpQIL from Israel (GenBank accession no. GU595196). 5, 35 Despite negative phenotypic detection of ESBLs, the isolate grouped within ST388 was positive for bla CTX-M-10 . We did not detect ESBL-bla SHV , qnrA, qnrB or qnrS genes, which have also been linked to KPC-3 in other countries, in any of the isolates. 36, 38, 39 bla KPC is located on Tn4401 within a pKPN3/4-like plasmid bla KPC-3 was part of a Tn4401 platform identical to those identified in plasmids carrying bla KPC-2 such as pNYC (80 kb, GenBank accession no. EU176011), pNGR (80 kb), 10 pKN633 (12 kb, GenBank accession no. EU176012), pCOL (45 kb, GenBank accession no. EU176013), pBC2303 (75, 35 kb, GenBank accession no. EU176014) or bla KPC-3 as pS12 (75 kb, GenBank accession no. FJ223605). It corresponded to the variant of Tn4401 designated as 'isoform a', which contains a 100 bp deletion between bla KPC and istB. This transposon type is usually associated with bla KPC-2 although it has also been detected in some KPC-3-producing isolates from Israel and Italy (Figure 2) . 5, 7, 10, 13, 14 As previously stated, we could not demonstrate an epidemiological link of our patients with known countries with KPC-3 isolates. The similarity in genetic background of our bla to that found for other bla KPC genes might also suggest a local emergence of the KPC-3 variant in our country, as this enzyme only differs from KPC-2 in one amino acid position (H272Y). 40 Nevertheless, this variant has not yet been reported in Spain.
All isolates carried a non-transferable plasmid of 85-90 kb (harbouring bla KPC-3 , bla OXA-9 and bla TEM-1 ) and a large plasmid ranging from 180 kb (all but one isolate) to 320 kb (one isolate) as reported for other KPC-producing strains. 5, 35 The KPC plasmids in ST384 isolates showed identical restriction fragment length polymorphism (RFLP) patterns, but a different pattern was found for the ST388 isolate. Both KPC plasmids showed a positive amplification with primers specific for the Salmonella FII virulence plasmids. 25 However, nucleotide sequences corresponding to the replicase and the relaxase obtained by the PCR schemes Figure 2 . Representation of Tn4401a harbouring bla KPC-3 and the PCR scheme used to amplify it. Arrows are drawn to scale. Isoform 'a' shows a 100 bp deletion upstream of bla KPC and it is detected among Tn4401 carrying bla KPC-2 as pNGR, pNYC (GenBank accession no. EU176011) and pS15 (GenBank accession no. FJ223606). Isoform 'b' is usually detected among Tn4401 carrying bla KPC-3 as pS12 (GenBank accession no. FJ223605) and bla KPC-2 as pS9 (GenBank accession no. FJ223607), pCOL (GenBank accession no. EU176013) and pBC2303 (GenBank accession no. EU176014).
used 25, 26 presented high homology (.97% identity) to those of the plasmids pKPN3, pKPN4 and pKpQIL from K. pneumoniae (GenBank accession numbers CP000648, CP000649 and GU595196), some of them previously associated with bla KPC genes. 6, 10, 13 Our results and those reports on plasmids of similar size amplifying with rep IncFII primers suggest a wide spread of these genetic elements. 6 
Conclusions
The emergence of Tn4401-bla KPC-3 located in a pKPN3/4-like plasmid within ST384 and ST388 carbapenem-resistant K. pneumoniae clones in Madrid (Spain) is described. Interestingly, both clones were newly recognized as being associated with KPC-3, ST388 being a persistent clone found in our institution since 1998 and harbouring the bla CTX-M-10 gene. Although KPC-3 producers have scarcely been reported in Europe, the location of Tn4401a-bla KPC-3 on widespread IncFII plasmids from Klebsiella, which can contain similar sequences to other enterobacterial plasmids also frequently identified among Klebsiella isolates, might fuel its future inter-clonal dissemination among isolates of the same or other genera by different horizontal gene processes. 36, 41, 42 This study also documents the penetration of bla KPC-3 genes within clinical K. pneumoniae clones in the central region of Spain that may become endemic as occurred in other European areas. Finally, this work highlights the role of endemic multiresistant clones as substrates of new antibiotic resistance genes, such as bla KPC-3 .
